1-3 of 3
Ryohei Kozaki
Close
Sort by
Journal Articles

ONO-7018, a First-in-Class MALT1 Inhibitor, Provides Novel Therapeutic Strategies for B Cell Malignancies: Overcoming BTK Inhibitor Acquired Resistance and Enhancing the Antitumor Effect of BTK Inhibitors

Ryu Fujikawa, Yuka Komichi, Kazuya Ono, Tomoko Yasuhiro, Sergio Prados, Takao Yoshida, Ryohei Kozaki
Journal: Blood
Blood (2023) 142 (Supplement 1): 5779.
https://doi.org/10.1182/blood-2023-185997
Published: 2023
Journal Articles

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Sean M Post, PhD, Huaxian Ma, MS, Vivian Ruvolo, Xiaorui Zhang, BS, Tomoko Yasuhiro, Kohei Tanaka, Ryohei Kozaki, Toshio Yoshizawa, PhD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Marina Y Konopleva, MD PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Michael Andreeff, MD PhD, Peter P. Ruvolo, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2550.
https://doi.org/10.1182/blood-2019-128626
Published: 2019
Journal Articles

Development of a Bruton's Tyrosine Kinase (Btk) Inhibitor, ONO-WG-307: Efficacy in ABC-DLBCL Xenograft Model – Potential Treatment for B-Cell Malignancies,

Ryohei Kozaki, Toshio Yoshizawa, Shuji Tohda, MD, PhD, Tomoko Yasuhiro, Shingo Hotta, Yuko Ariza, Yoshiko Ueda, Masami Narita, Kazuhito Kawabata
Journal: Blood
Blood (2011) 118 (21): 3731.
https://doi.org/10.1182/blood.V118.21.3731.3731
Published: 2011